Compounds > 6,7-dichloro-3-hydroxy-2-quinoxalinecarboxylic acid
Page last updated: 2024-12-10

6,7-dichloro-3-hydroxy-2-quinoxalinecarboxylic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

6,7-dichloro-3-hydroxy-2-quinoxalinecarboxylic acid: antagonist of N-methyl-D-aspartic acid and kainate receptors; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3018579
CHEMBL ID130213
CHEBI ID166582
SCHEMBL ID4287210
MeSH IDM0161216

Synonyms (35)

Synonym
6,7-dichloro-3-hydroxy-2-quinoxalinecarboxylicacid
CHEBI:166582
75294-00-7
DIVK1C_006821
2-quinoxalinecarboxylic acid, 6,7-dichloro-3,4-dihydro-3-oxo-
6,7-dichloro-3-oxo-4h-quinoxaline-2-carboxylic acid
SPECTRUM_001459
SPECTRUM5_001919
BSPBIO_002612
NCGC00095883-01
KBIO2_001939
KBIO2_007075
KBIO3_001832
KBIOGR_001891
KBIO1_001765
KBIO2_004507
KBIOSS_001939
SPECTRUM3_001056
SPECTRUM4_001196
SPBIO_000393
SPECPLUS_000725
SPECTRUM2_000497
SPECTRUM1502070
NCGC00095883-02
CHEMBL130213
6,7-dichloro-3-hydroxy-2-quinoxalinecarboxylic acid
dicl-hqc
CCG-39579
SCHEMBL4287210
6,7-dichloro-3-keto-4h-quinoxaline-2-carboxylic acid
6,7-dichloro-3-oxo-3,4-dihydroquinoxaline-2-carboxylic acid
6,7-dichloro-3,4-dihydro-3-oxo-2-quinoxalinecarboxylic acid
FT-0764488
DTXSID70996749
PD001400
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
quinoxaline derivativeAny naphthyridine derivative that is a derivative of quinoxaline (1,4-naphthyridine).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (8)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
lamin isoform A-delta10Homo sapiens (human)Potency25.11890.891312.067628.1838AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Glutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)IC50 (µMol)0.46000.00071.600310.0000AID145260
Glutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)IC50 (µMol)0.46000.00071.630610.0000AID145260
Glutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)IC50 (µMol)0.46000.00061.525710.0000AID145260
Glutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)IC50 (µMol)0.46000.00071.747210.0000AID145260
Glutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)IC50 (µMol)0.46000.00071.741110.0000AID145260
Glutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)IC50 (µMol)0.46000.00071.741110.0000AID145260
Glutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)IC50 (µMol)0.46000.00071.741110.0000AID145260
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (27)

Assay IDTitleYearJournalArticle
AID1347161Confirmatory screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347157Confirmatory screen GU Rhodamine qHTS for Zika virus inhibitors qHTS2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347149Furin counterscreen qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347169Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1578468Unbound tissue partition coefficient, ratio of drug level in heart to plasma in Wistar Han rat at 1 to 2 mg/kg, iv infused for 10 to 20 hrs by LC-MS/MS analysis2020European journal of medicinal chemistry, Jan-01, Volume: 185Structural attributes influencing unbound tissue distribution.
AID1578470Unbound tissue partition coefficient, ratio of drug level in adipose to plasma in Wistar Han rat at 1 to 2 mg/kg, iv infused for 10 to 20 hrs by LC-MS/MS analysis2020European journal of medicinal chemistry, Jan-01, Volume: 185Structural attributes influencing unbound tissue distribution.
AID1578460Fraction unbound in Wistar Han rat liver at 2 uM incubated for 6 hrs by equilibrium dialysis method2020European journal of medicinal chemistry, Jan-01, Volume: 185Structural attributes influencing unbound tissue distribution.
AID145260In vitro inhibition of [3H]glycine at NMDA receptor1994Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24
The glycine site on the NMDA receptor: structure-activity relationships and therapeutic potential.
AID1578465Drug concentration in total heart in Wistar Han rat at 1 to 2 mg/kg, iv infused for 10 to 20 hrs by LC-MS/MS analysis2020European journal of medicinal chemistry, Jan-01, Volume: 185Structural attributes influencing unbound tissue distribution.
AID1578463Drug concentration in total white adipose tissue in Wistar Han rat at 1 to 2 mg/kg, iv infused for 10 to 20 hrs by LC-MS/MS analysis2020European journal of medicinal chemistry, Jan-01, Volume: 185Structural attributes influencing unbound tissue distribution.
AID1578456Fraction unbound in Wistar Han rat plasma at 2 uM incubated for 6 hrs by equilibrium dialysis method2020European journal of medicinal chemistry, Jan-01, Volume: 185Structural attributes influencing unbound tissue distribution.
AID1578462Total plasma concentration in Wistar Han rat at 1 to 2 mg/kg, iv infused for 10 to 20 hrs by LC-MS/MS analysis2020European journal of medicinal chemistry, Jan-01, Volume: 185Structural attributes influencing unbound tissue distribution.
AID1578458Fraction unbound in Wistar Han rat brain at 2 uM incubated for 6 hrs by equilibrium dialysis method2020European journal of medicinal chemistry, Jan-01, Volume: 185Structural attributes influencing unbound tissue distribution.
AID1578459Fraction unbound in Wistar Han rat heart at 2 uM incubated for 6 hrs by equilibrium dialysis method2020European journal of medicinal chemistry, Jan-01, Volume: 185Structural attributes influencing unbound tissue distribution.
AID1578474Apparent permeability of the compound across dog RRCK cells by MDCK-LE assay2020European journal of medicinal chemistry, Jan-01, Volume: 185Structural attributes influencing unbound tissue distribution.
AID1578464Drug concentration in total brain in Wistar Han rat at 1 to 2 mg/kg, iv infused for 10 to 20 hrs by LC-MS/MS analysis2020European journal of medicinal chemistry, Jan-01, Volume: 185Structural attributes influencing unbound tissue distribution.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1578461Fraction unbound in Wistar Han rat skeletal muscle at 2 uM incubated for 6 hrs by equilibrium dialysis method2020European journal of medicinal chemistry, Jan-01, Volume: 185Structural attributes influencing unbound tissue distribution.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1578457Fraction unbound in Wistar Han rat white adipose tissue at 2 uM incubated for 6 hrs by equilibrium dialysis method2020European journal of medicinal chemistry, Jan-01, Volume: 185Structural attributes influencing unbound tissue distribution.
AID1578469Unbound tissue partition coefficient, ratio of drug level in brain to plasma in Wistar Han rat at 1 to 2 mg/kg, iv infused for 10 to 20 hrs by LC-MS/MS analysis2020European journal of medicinal chemistry, Jan-01, Volume: 185Structural attributes influencing unbound tissue distribution.
AID1578466Drug concentration in total liver in Wistar Han rat at 1 to 2 mg/kg, iv infused for 10 to 20 hrs by LC-MS/MS analysis2020European journal of medicinal chemistry, Jan-01, Volume: 185Structural attributes influencing unbound tissue distribution.
AID1578472Unbound tissue partition coefficient, ratio of drug level in skeletal muscle to plasma in Wistar Han rat at 1 to 2 mg/kg, iv infused for 10 to 20 hrs by LC-MS/MS analysis2020European journal of medicinal chemistry, Jan-01, Volume: 185Structural attributes influencing unbound tissue distribution.
AID1578471Unbound tissue partition coefficient, ratio of drug level in liver to plasma in Wistar Han rat at 1 to 2 mg/kg, iv infused for 10 to 20 hrs by LC-MS/MS analysis2020European journal of medicinal chemistry, Jan-01, Volume: 185Structural attributes influencing unbound tissue distribution.
AID1578467Drug concentration in total skeletal muscle in Wistar Han rat at 1 to 2 mg/kg, iv infused for 10 to 20 hrs by LC-MS/MS analysis2020European journal of medicinal chemistry, Jan-01, Volume: 185Structural attributes influencing unbound tissue distribution.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (18.18)18.7374
1990's4 (36.36)18.2507
2000's0 (0.00)29.6817
2010's3 (27.27)24.3611
2020's2 (18.18)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.02

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.02 (24.57)
Research Supply Index2.48 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.02)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (18.18%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (81.82%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
1-aminocyclopropane-1-carboxylic acid
1-aminocyclopropanecarboxylic acid : A non-proteinogenic alpha-amino acid consisting of cyclopropane having amino and carboxy substituents both at the 1-position.		3.0810amino acid zwitterion;
monocarboxylic acid;
non-proteinogenic alpha-amino acid		ethylene releasers;
plant metabolite
glycine
[no description available]		3.7830alpha-amino acid;
amino acid zwitterion;
proteinogenic amino acid;
serine family amino acid		EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor;
fundamental metabolite;
hepatoprotective agent;
micronutrient;
neurotransmitter;
NMDA receptor agonist;
nutraceutical
alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid: An IBOTENIC ACID homolog and glutamate agonist. The compound is the defining agonist for the AMPA subtype of glutamate receptors (RECEPTORS, AMPA). It has been used as a radionuclide imaging agent but is more commonly used as an experimental tool in cell biological studies.		2.3820non-proteinogenic alpha-amino acid
ibotenic acid
Ibotenic Acid: A neurotoxic isoxazole (similar to KAINIC ACID and MUSCIMOL) found in AMANITA mushrooms. It causes motor depression, ataxia, and changes in mood, perceptions and feelings, and is a potent excitatory amino acid agonist.		1.9710non-proteinogenic alpha-amino acidneurotoxin
5,7-dichlorokynurenic acid
5,7-dichlorokynurenic acid: potent antagonist at the N-methyl-D-aspartate receptor-associated glycine binding site		3.0810quinolines
6,7-dichloroquinoxaline-2,3-dione
[no description available]		3.0810quinoxaline derivative
7-chlorokynurenic acid
7-chlorokynurenic acid: selective antagonist at the glycine modulatory site of the N-methyl-D-aspartate receptor complex; structure given in first source. 7-chlorokynurenic acid : A quinolinemonocarboxylic acid that is quinaldic acid which is substituted by a hydroxy group at position 4 and by a chlorine at position 7. It is a potent NMDA glutamate receptor antagonist which antagonizes the strychnine-insensitive glycine site of the NMDA receptor. It also prevents neurodegeneration produced by quinolinic acid.		3.0810organochlorine compound;
quinolinemonocarboxylic acid		neuroprotective agent;
NMDA receptor antagonist
kynurenic acid
Kynurenic Acid: A broad-spectrum excitatory amino acid antagonist used as a research tool.. kynurenic acid : A quinolinemonocarboxylic acid that is quinoline-2-carboxylic acid substituted by a hydroxy group at C-4.		3.0810monohydroxyquinoline;
quinolinemonocarboxylic acid		G-protein-coupled receptor agonist;
human metabolite;
neuroprotective agent;
nicotinic antagonist;
NMDA receptor antagonist;
Saccharomyces cerevisiae metabolite
loperamide
Loperamide: One of the long-acting synthetic ANTIDIARRHEALS; it is not significantly absorbed from the gut, and has no effect on the adrenergic system or central nervous system, but may antagonize histamine and interfere with acetylcholine release locally.. loperamide : A synthetic piperidine derivative, effective against diarrhoea resulting from gastroenteritis or inflammatory bowel disease.		2.2510monocarboxylic acid amide;
monochlorobenzenes;
piperidines;
tertiary alcohol		anticoronaviral agent;
antidiarrhoeal drug;
mu-opioid receptor agonist
prazosin
Prazosin: A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION.. prazosin : A member of the class of piperazines that is piperazine substituted by a furan-2-ylcarbonyl group and a 4-amino-6,7-dimethoxyquinazolin-2-yl group at positions 1 and 4 respectively.		2.2510aromatic ether;
furans;
monocarboxylic acid amide;
piperazines;
quinazolines		alpha-adrenergic antagonist;
antihypertensive agent;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
cycloserine
Cycloserine: Antibiotic substance produced by Streptomyces garyphalus.. D-cycloserine : A 4-amino-1,2-oxazolidin-3-one that has R configuration. It is an antibiotic produced by Streptomyces garyphalus or S. orchidaceus and is used as part of a multi-drug regimen for the treatment of tuberculosis when resistance to, or toxicity from, primary drugs has developed. An analogue of D-alanine, it interferes with bacterial cell wall synthesis in the cytoplasm by competitive inhibition of L-alanine racemase (which forms D-alanine from L-alanine) and D-alanine--D-alanine ligase (which incorporates D-alanine into the pentapeptide required for peptidoglycan formation and bacterial cell wall synthesis).		3.08104-amino-1,2-oxazolidin-3-one;
organonitrogen heterocyclic antibiotic;
organooxygen heterocyclic antibiotic;
zwitterion		antiinfective agent;
antimetabolite;
antitubercular agent;
metabolite;
NMDA receptor agonist
phencyclidine
Phencyclidine: A hallucinogen formerly used as a veterinary anesthetic, and briefly as a general anesthetic for humans. Phencyclidine is similar to KETAMINE in structure and in many of its effects. Like ketamine, it can produce a dissociative state. It exerts its pharmacological action through inhibition of NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE). As a drug of abuse, it is known as PCP and Angel Dust.. phencyclidine : A member of the class of piperidines that is piperidine in which the nitrogen is substituted with a 1-phenylcyclohexyl group. Formerly used as an anaesthetic agent, it exhibits both hallucinogenic and neurotoxic effects.		1.9810benzenes;
piperidines		anaesthetic;
neurotoxin;
NMDA receptor antagonist;
psychotropic drug
quinoxalines
quinoxaline : A naphthyridine in which the nitrogens are at positions 1 and 4.		3.0850mancude organic heterobicyclic parent;
naphthyridine;
ortho-fused heteroarene
kainic acid
Kainic Acid: (2S-(2 alpha,3 beta,4 beta))-2-Carboxy-4-(1-methylethenyl)-3-pyrrolidineacetic acid. Ascaricide obtained from the red alga Digenea simplex. It is a potent excitatory amino acid agonist at some types of excitatory amino acid receptors and has been used to discriminate among receptor types. Like many excitatory amino acid agonists it can cause neurotoxicity and has been used experimentally for that purpose.		2.6730dicarboxylic acid;
L-proline derivative;
non-proteinogenic L-alpha-amino acid;
pyrrolidinecarboxylic acid		antinematodal drug;
excitatory amino acid agonist
n-methylaspartate
N-Methylaspartate: An amino acid that, as the D-isomer, is the defining agonist for the NMDA receptor subtype of glutamate receptors (RECEPTORS, NMDA).. N-methyl-D-aspartic acid : An aspartic acid derivative having an N-methyl substituent and D-configuration.		1.9910amino dicarboxylic acid;
D-alpha-amino acid;
D-aspartic acid derivative;
secondary amino compound		neurotransmitter agent
2,3-dihydroxyquinoxaline
2,3-dihydroxyquinoxaline: fluorescent oxalic acid deriv.		3.0810
quisqualic acid
Quisqualic Acid: An agonist at two subsets of excitatory amino acid receptors, ionotropic receptors that directly control membrane channels and metabotropic receptors that indirectly mediate calcium mobilization from intracellular stores. The compound is obtained from the seeds and fruit of Quisqualis chinensis.		2.3820non-proteinogenic alpha-amino acid
tenocyclidine
tenocyclidine : A tertiary amino compound that consists of cyclohexane having piperidin-1-yl and thiophen-2-yl groups attached at position 1. A dissociative anaesthetic drug with halluccinogenic and stimulant effects. Its effects are similar to those of phencyclidine (PCP, an analogue with the thienyl group replaced by phenyl), but it is rather more potent.		1.9810piperidines;
tertiary amino compound;
thiophenes		central nervous system stimulant;
hallucinogen;
neuroprotective agent;
NMDA receptor antagonist
D-serine
[no description available]		3.0810D-alpha-amino acid;
serine zwitterion;
serine		Escherichia coli metabolite;
human metabolite;
NMDA receptor agonist
1-aminocyclobutanecarboxylic acid
1-aminocyclobutanecarboxylic acid: RN given refers to unlabeled cpd		3.0810L-alpha-amino acid
rpr 104632
RPR 104632: structure given in first source		3.0810
ritonavir
Ritonavir: An HIV protease inhibitor that works by interfering with the reproductive cycle of HIV. It also inhibits CYTOCHROME P-450 CYP3A.. ritonavir : An L-valine derivative that is L-valinamide in which alpha-amino group has been acylated by a [(2-isopropyl-1,3-thiazol-4-yl)methyl]methylcarbamoyl group and in which a hydrogen of the carboxamide amino group has been replaced by a (2R,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl group. A CYP3A inhibitor and antiretroviral drug from the protease inhibitor class used to treat HIV infection and AIDS, it is often used as a fixed-dose combination with another protease inhibitor, lopinavir. Also used in combination with dasabuvir sodium hydrate, ombitasvir and paritaprevir (under the trade name Viekira Pak) for treatment of chronic hepatitis C virus genotype 1 infection as well as cirrhosis of the liver.		2.25101,3-thiazoles;
carbamate ester;
carboxamide;
L-valine derivative;
ureas		antiviral drug;
environmental contaminant;
HIV protease inhibitor;
xenobiotic
mdl29,951
[no description available]		3.0810
ketoconazole
(2R,4S)-ketoconazole : A cis-1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine which dioxolane moiety has (2R,4S)-configuration.		2.2510cis-1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine
7-chloro-thiokynurenate
7-chlorothiokynurenic acid: glycine site antagonist of NMDA receptor		3.0810
6-cyano-7-nitroquinoxaline-2,3-dione
6-Cyano-7-nitroquinoxaline-2,3-dione: A potent excitatory amino acid antagonist with a preference for non-NMDA iontropic receptors. It is used primarily as a research tool.		2.3920quinoxaline derivative
fg 9041
FG 9041: structure given in first source		3.0810quinoxaline derivative
alvocidib
alvocidib: structure given in first source. alvocidib : A synthetic dihydroxyflavone that is 5,7-dihydroxyflavone which is substituted by a 3-hydroxy-1-methylpiperidin-4-yl group at position 8 and by a chlorine at the 2' position (the (-)-3S,4R stereoisomer). A cyclin-dependent kinase 9 (CDK9) inhibitor, it has been studied for the treatment of acute myeloid leukaemia, arthritis and atherosclerotic plaque formation.		2.2510dihydroxyflavone;
hydroxypiperidine;
monochlorobenzenes;
tertiary amino compound		antineoplastic agent;
antirheumatic drug;
apoptosis inducer;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
licostinel
licostinel: a glycine site NMDA receptor antagonist; structure given in first source		3.0810
l 689560
[no description available]		3.0810quinolines
oxadiazoles
Oxadiazoles: Compounds containing five-membered heteroaromatic rings containing two carbons, two nitrogens, and one oxygen atom which exist in various regioisomeric forms.		1.9710
e 2012
[no description available]		2.2510
l 701324
L 701324: a glycine/NMDA receptor antagonist		3.0810quinolines
7-chloro-3-[cyclopropyl(oxo)methyl]-4-hydroxy-1H-quinolin-2-one
[no description available]		3.0810hydroxyquinoline;
quinolone
concanavalin a
Concanavalin A: A MANNOSE/GLUCOSE binding lectin isolated from the jack bean (Canavalia ensiformis). It is a potent mitogen used to stimulate cell proliferation in lymphocytes, primarily T-lymphocyte, cultures.		1.9810
ConditionIndicatedRelationship StrengthStudiesTrials
Benign Neoplasms
[description not available]		03.0310
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		03.0310
Anemia, Fanconi
[description not available]		02.1310
Fanconi Anemia
Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004)		02.1310
Congenital Zika Syndrome
[description not available]		02.2510
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.2510
Zika Virus Infection
A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.		02.2510